ClinicalTrials.gg
RecruitingNCT07047014ARTS-MeVOUpdated Apr 1, 2026

Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke

A Phase 3 interventional study of Tenecteplase (0.25mg/kg) and Standard medical treatment in Stroke, Ischemic and Medium Vessel Occlusions, sponsored by Beijing Tiantan Hospital. Recruiting at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Beijing Tiantan Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
596
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 59 studies testing tenecteplase in Ischemic Stroke — 32 open to participants now, 32 under way, 25 of them phase 3. Tenecteplase · Ischemic Stroke.

Planned enrollment
23rd of 59
596 · median 466
Started
2025
with 10 others
Phase 3
37 of 59
23 open now
Primary completion
2027-03
later than 8 of 31 live
Registered
42nd of 59
by date
Lead sponsor
11 of 59
Beijing Tiantan Hospital

Among the 59 studies testing tenecteplase in Ischemic Stroke, this one is the 23rd largest by planned enrollment, is one of 11 that started in 2025, is one of 37 in phase 3, reaches primary completion later than 8 of the 31 other live ones, and was the 42nd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

32 of the 59 studies testing tenecteplase in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About tenecteplase

Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing tenecteplase in Ischemic Stroke, or all of them as a file.
02

Study summary

Results from recent several trials provided data showing limits to the effectiveness of thrombectomy for ischemic stroke due to medium vessel occlusions.The benefit-risk profile of thrombolysis for these patients has never been investigated. We initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of tenecteplase (0.25mg/kg, maximum dose 25mg) compared to standard medical care for patients with acute ischemic stroke due to medium vessel occlusion (MeVO) within 4.5 to 24 hours from symptom onset.

Read the detailed description

Adult acute ischemic stroke patients due to primary medium vessel occlusions (distal M2/M3 segments of the middle cerebral artery, A1/A2/A3 segments of the anterior cerebral artery, and P1/P2/P3 segments of the posterior cerebral artery confirmed by CTA/MRA, and responsible for the signs and symptoms of acute ischemic stroke) with baseline National Institutes of Health Stroke Scale (NIHSS) ≥6 or NIHSS 3-5 with disabling symptoms will be enrolled in this trial. We use perfusion imaging to select subjects and the enrolled patients have target mismatch profile on CTP or MRI+PWI (ischemic core volume \<70mL, mismatch ratio>1.2, mismatch volume >10mL). If neither MRI or CT perfusion is available at the site, an ASPECTS/PC-ASPECTS of 8 or more on NCCT /MRI-DWI will be used.We will randomly assign eligible patients to receive tenecteplase (at a dose of 0.25 mg per kilogram of body weight; maximum dose, 25 mg) or standard medical treatment 4.5 to 24 hours after the time that the patient was last known to be well (including after stroke on awakening and unwitnessed stroke). The primary outcome is the proportion of patients with an mRS score ≤ 1 at 90 days.

03

Conditions studied

  • Stroke, Ischemic
  • Medium Vessel Occlusions

Browse trials for

Keywords

  • ischemic stroke
  • tenecteplase
  • medium vessel occlusions
  • beyond 4.5 hours
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1)Age≥18 years old;
  • (2)Acute ischemic stroke symptom onset within 4.5 - 24 hours; including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time";
  • (3)Primary medium vessel occlusions confirmed by CTA/MRA, including distal M2/M3 segments of the middle cerebral artery (MCA), A1/A2/A3 segments of the anterior cerebral artery (ACA), and P1/P2/P3 segments of the posterior cerebral artery (PCA) and responsible for the signs and symptoms of acute ischemic stroke;
  • (4)Neuroimaging criteria: a) Perfusion criteria:Target mismatch profile on CT perfusion or MRI+MR perfusion (ischemic core volume \<70mL, mismatch ratio >1.2, mismatch volume >10mL); b) If neither MRI or CT perfusion is available at the site : an Alberta Stroke Program Early CT Score [ASPECTS] of 8 or more on NCCT /MRI-DWI or PC-ASPECTS of 8 or more on NCCT/MRI-DWI.
  • (5)Pre-stroke modified Rankin scale (mRS) score ≤1;
  • (6)Baseline National Institutes of Health Stroke Scale (NIHSS) ≥6 or NIHSS 3-5 with disabling symptoms;
  • (7)Written from patients or their legally authorized representatives.

Exclusion criteria

Exclusion Criteria:

  • (1)Allergy to tenecteplase;
  • (2)Rapidly improving symptoms at the discretion of the investigator;
  • (3)NIHSS consciousness score 1a >2, or epileptic seizure, hemiplegia after seizures (Todd's palsy) or other neurological/mental illness such that the patient is not able to cooperate or unwilling to cooperate;
  • (4)Intention to undergo endovascular treatment.
  • (5)Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), despite blood pressure-lowering treatment;
  • (6)Blood glucose \<2.8 or >22.2 mmol/L (point of care glucose testing is acceptable);
  • (7) Active internal bleeding or at high risk of bleeding, e.g., major surgery, trauma or gastrointestinal or urinary tract hemorrhage within the previous 21 days, or arterial puncture at a non-compressible site within the previous 7 days;
  • (8)Any known impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, then >1.7 or prothrombin time >15 seconds; use of any direct thrombin inhibitors or direct factor Xa inhibitors during the last 48 hours unless reversal of dabigatran can be achieved with idarucizumab; any full dose heparin/heparinoid during the last 24 hours or with an APTT greater than the ;
  • (9)Known defect of function or platelet count below 100,000/mm3 (NB patients taking antiplatelet medication can be included);
  • (10)Ischemic stroke or myocardial infarction in previous 3 months, previous intracranial hemorrhage, severe traumatic brain injury or intracranial or intraspinal operation in previous 3 months, or known intracranial neoplasm, arteriovenous malformation, or giant aneurysm;
  • (11)Any terminal illness such that the patient would not be expected to survive more than 1 year;
  • (12) Unable to perform CTP or PWI;
  • (13)Hypodensity in >1/3 MCA territory on non-contrast CT or hypodensity outside the current perfusion lesion suggesting distal clot migration (secondary MeVO);
  • (14)Acute or past intracerebral hemorrhage (ICH) identified by CT or MRI;
  • (15)Pregnant women, nursing mothers, or reluctance to use effective measures during the period of the trial;
  • (16)Unlikely to adhere to the trial protocol or follow-up;
  • (17) Participation in other interventional clinical trials within the previous 3 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
596 participants (estimated)

Study arms

  • Experimental
    Tenecteplase (0.25 mg/kg)

    Tenecteplase (0.25 mg/kg, max 25 mg)

    Drug: Tenecteplase (0.25mg/kg)

  • Active comparator
    Standard medical treatment

    Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone, etc.

    Drug: Standard medical treatment

Interventions

  • DrugTenecteplase (0.25mg/kg)

    Drug page: TenecteplaseStudies of TenecteplaseTenecteplase pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each vial of tenecteplase is reconstituted with 3 ml sterile water for injection and adjusted to a concentration of 5.33 mg/ml. Calculate the total amount of drug according to the subject's actual body weight and measure the required drug volume. The maximum dose should not exceed 25mg. Tenecteplase should be given as a single, intravenous bolus (within 5-10 seconds).

  • DrugStandard medical treatment

    Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of site researchers according to Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023.

06

What researchers measure

Primary outcomes

  1. mRS score ≤ 1 at 90 days

    The proportion of patients with an mRS score ≤ 1 at 90 days

    Time frame: 90 days

Secondary outcomes

  1. mRS score

    Ordinal distribution of mRS at 90 days (shift analysis)

    Time frame: 90 days

  2. mRS score ≤ 2

    The proportion of patients with an mRS score of 0-2 at 90 days

    Time frame: 90 days

  3. Early neurological improvement

    The rate of early neurological improvement at 24h after randomization (defined as a NIHSS score ≤1 or ≥4 points compared with the baseline)

    Time frame: 24 hours

  4. mRS 5-6

    mRS 5-6 at 90 days

    Time frame: 90 days

  5. EuroQol 5-Dimension (EQ-5D) index

    EuroQol 5-Dimension (EQ-5D) index at 90 days and 1 year

    Time frame: 90 days and 1 year

  6. mRS score at 1 year

    mRS score at 1 year

    Time frame: 1 year

  7. Symptomatic intracranial hemorrhage

    Symptomatic intracranial hemorrhage within 36 hours (defined by the SITS-MOST criteria)

    Time frame: 36 hours

  8. All-cause mortality

    All-cause mortality at 90 days and 1 year

    Time frame: 90 days and 1 year

  9. Systemic bleeding

    Systemic bleeding at 90 days (defined by the GUSTO criteria: moderate and severe bleeding)

    Time frame: 90 days

  10. Adverse events (AEs)/ serious adverse events (SAEs)

    Adverse events (AEs)/ serious adverse events (SAEs) within 90 days

    Time frame: 90 days

07

Study locations

5 of 7 sites recruiting
  • Beijing tiantan hospital
    Beijing, Beijing Municipality 100070, China
    Not yet recruiting
  • Jiuquan city people's hospital
    Jiuquan, Gansu 736100, China
    Recruiting
  • Xingtang People's Hospital
    Shijiazhuang, Hebei 050600, China
    Recruiting
  • Jiyuan Traditional Chinese Medicine Hospital
    Jiyuan, Henan 459000, China
    Recruiting
  • The first people hospital of lingbao
    Lingbao, Henan 472500, China
    Recruiting
  • Hai'an People's Hospital
    Nantong, Jiangsu 226600, China
    Recruiting
  • The First Affiliated Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 20 months after the start.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 20 months is below that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 2, 2025
StartActual
Jul 30, 2025
Primary completionEst.
Mar 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07047014
Collaborators
First Affiliated Hospital of Zhejiang University, Chinese Stroke Association
Responsible party
Yunyun Xiong (Professor, Beijing Tiantan Hospital) — Principal investigator
First posted
Jul 2, 2025
Start date
Jul 30, 2025
Primary completion
Mar 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Apr 1, 2026

Study contacts

Yunyun Xiong
Contact
xiongyunyun@bjtth.org
86-10-59978350
Ziqi Xu
Contact
zyxuziqi@zju.edu.cn
86-0571-87236666
Ziqi Xu
principal investigator · First Affiliated Hospital of Zhejiang University
Yunyun Xiong
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion